Sections
| Title | Starting Page | Number of Pages |
|---|
| 1 Table of Contents | 2 | 3 |
| 1.1 List of Tables | 3 | 1 |
| 1.2 List of Figures | 3 | 2 |
| 2 Executive Summary | 5 | 1 |
| 2.1 A Crowded, Competitive Market, with Significant Unmet Needs Remaining | 5 | 1 |
| 2.2 Early-Stage Pipeline Offers Greatest Promise for First-in-Class Innovation | 5 | 1 |
| 2.3 Cytokine and Cytokine Receptors, as well as Protein Kinases, Largely Dominate First-in-Class Pipeline Products | 5 | 1 |
| 3 The Case for Innovation | 6 | 4 |
| 3.1 Growing Opportunities for Biologic Products | 7 | 1 |
| 3.2 Diversification of Molecular Targets | 7 | 1 |
| 3.3 Innovative First-in-Class Development Remains Attractive | 8 | 1 |
| 3.4 Regulatory and Reimbursement Policy Shifts Favor First-in-Class Product Innovation | 8 | 1 |
| 3.5 Sustained Innovation | 8 | 1 |
| 3.6 GBI Research Report Guidance | 9 | 1 |
| 4 Clinical and Commercial Landscape | 10 | 7 |
| 4.1 Disease Overview | 10 | 1 |
| 4.2 Disease Symptoms | 10 | 1 |
| 4.3 Epidemiology | 11 | 1 |
| 4.4 Etiology | 11 | 1 |
| 4.5 Pathophysiology | 11 | 1 |
| 4.6 Co-morbidities and Complications | 12 | 1 |
| 4.7 Diagnosis | 12 | 1 |
| 4.7.1 Blood Tests | 12 | 1 |
| 4.7.1.1 Rheumatoid Factor Test | 12 | 1 |
| 4.7.1.2 Anti-Citrullinated Protein Antibody | 12 | 1 |
| 4.7.1.3 C-Reactive Protein | 12 | 1 |
| 4.7.1.4 Erythrocyte Sedimentation Rate | 12 | 1 |
| 4.7.1.5 X-Ray Imaging | 13 | 1 |
| 4.7.2 1987 Rheumatoid Arthritis Classification | 13 | 1 |
| 4.7.3 2010 ACR-EULAR Classification Criteria for Rheumatoid Arthritis | 13 | 1 |
| 4.8 Disease Progression | 13 | 1 |
| 4.9 Treatment Options and Treatment Algorithm | 14 | 1 |
| 4.10 28TOverview of Marketed Products in Rheumatoid Arthritis | 15 | 1 |
| 4.10.1 Molecule Type and Molecular Target Analysis | 15 | 2 |
| 5 Assessment of Pipeline Product Innovation | 17 | 15 |
| 5.1 Rheumatoid Arthritis Pipeline by Stage of Development, Molecule Type and Molecular Target | 17 | 4 |
| 5.2 Comparative Distribution of Programs between the Rheumatoid Arthritis Market and Pipeline by Therapeutic Target Family | 21 | 1 |
| 5.3 First-in-Class Programs Targeting Novel Molecular Targets | 21 | 11 |
| 6 Signaling Network, Disease Causation and Innovation Alignment | 32 | 5 |
| 6.1 Complexity of Signaling Networks in Rheumatoid Arthritis | 32 | 1 |
| 6.2 Signaling Pathways, Disease-Causing Mutations and First-in-Class Molecular Target Integration | 33 | 1 |
| 6.3 First-in-Class Matrix Assessment | 33 | 4 |
| 7 First-in-Class Target Evaluation | 37 | 11 |
| 7.1 Pipeline Programs Targeting Tumor Necrosis Factor Receptor Superfamily Member 5 (CD40) | 37 | 1 |
| 7.2 Pipeline Programs Targeting Non-Receptor Tyrosine-Protein Kinase TYK2 (TYK2) | 38 | 1 |
| 7.3 Pipeline Programs Targeting IL-10 and IL-18 | 39 | 2 |
| 7.4 Pipeline Programs Targeting 72 kDa Type IV Collagenase (MMP2) | 41 | 1 |
| 7.5 Pipeline Programs Targeting P2X Purinoceptor 7 (P2RX7) | 42 | 1 |
| 7.6 Pipeline Programs Targeting Protein Kinase C Theta Type (PRKCQ) | 43 | 1 |
| 7.7 Pipeline Programs Targeting C-C Motif Chemokine 4 (CCL4) and C-C Motif Chemokine 5 (CCL5) | 44 | 2 |
| 7.8 Pipeline Programs Targeting C-X-C Motif Chemokine 10 (CXCL10) and C-X-C Motif Chemokine 13 (CXCL13) | 46 | 2 |
| 8 Strategic Consolidations | 48 | 11 |
| 8.1 Industry-Wide First-in-Class Deals | 48 | 1 |
| 8.2 Licensing Deals | 49 | 3 |
| 8.3 Co-development Deals | 52 | 4 |
| 8.4 First-in-Class Programs Not Involved in Licensing or Co-development Deals | 56 | 3 |
| 9 Appendix | 59 | 8 |
| 9.1 References | 59 | 4 |
| 9.2 Abbreviations | 63 | 1 |
| 9.3 Research Methodology | 64 | 1 |
| 9.4 Secondary Research | 64 | 3 |
| 9.4.1 Market Analysis | 64 | 1 |
| 9.4.2 Pipeline Analysis | 65 | 1 |
| 9.4.2.1 Overall Pipeline | 65 | 1 |
| 9.4.2.2 First-in-Class Analysis | 65 | 1 |
| 9.4.3 First-in-Class Matrix Assessment | 65 | 1 |
| 9.4.4 First-in-Class Target Profiles | 65 | 1 |
| 9.4.5 Licensing and Co-Development Deals | 66 | 1 |
| 9.5 Contact Us | 66 | 1 |
| 9.6 Disclaimer | 66 | 1 |